CAMP (Camp4 Therapeutics) Cash-to-Debt : 0.27 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Camp4 Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Camp4 Therapeutics's cash to debt ratio for the quarter that ended in Sep. 2024 was 0.27.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Camp4 Therapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Camp4 Therapeutics's Cash-to-Debt or its related term are showing as below:

CAMP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.27 Med: 2.26 Max: 6.71
Current: 0.27

During the past 2 years, Camp4 Therapeutics's highest Cash to Debt Ratio was 6.71. The lowest was 0.27. And the median was 2.26.

CAMP's Cash-to-Debt is ranked worse than
89.17% of 1487 companies
in the Biotechnology industry
Industry Median: 6.38 vs CAMP: 0.27

Camp4 Therapeutics Cash-to-Debt Historical Data

The historical data trend for Camp4 Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Camp4 Therapeutics Cash-to-Debt Chart

Camp4 Therapeutics Annual Data

Trend

Dec22

Dec23

Cash-to-Debt

6.71

3.28

Camp4 Therapeutics Quarterly Data
	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial			N/A	N/A	3.28	1.23	0.27

Competitive Comparison of Camp4 Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Camp4 Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Camp4 Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camp4 Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Camp4 Therapeutics's Cash-to-Debt falls into.

Camp4 Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Camp4 Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	38.38	/	(3.058	+	8.635)
	=	3.28

Camp4 Therapeutics's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.528	/	(3.089	+	6.361)
	=	0.27

Camp4 Therapeutics (NAS:CAMP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Camp4 Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Camp4 Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Camp4 Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camp4 Therapeutics Corp (NAS:CAMP) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA

Website

https://www.camp4tx.com

Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.

Camp4 Therapeutics Headlines

From GuruFocus

Camp4 Therapeutics (CAMP) Sees Steady Start with NASDAQ Debut

By GuruFocus News • 10-11-2024

CAMP4 Announces Pricing of Initial Public Offering

By Marketwired • 10-11-2024

CAMP4 Reports Third Quarter 2024 Financial Results

By Marketwired • 11-21-2024

CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference

By Marketwired • 12-02-2024